Table 3 Comparison of the early mortality risk groups according to the localization of embolism, COVID-19 treatment

Male gender

38 (71.7)

9 (50.0)

11 (68.8)

0.24

0.85

Presence of pneumonia

42 (79.2)

15 (83.3)

12 (75.0)

0.87*

0.73*

Presence of comorbidity

33 (62.3)

13 (72.2)

13 (81.3)

0.33

0.20

Diagnosed with SARS-CoV-2 PCR

38 (71.7)

13 (72.2)

8 (50.0)

0.24

0.091

Diagnosed with thoracic CT

15 (28.3)

5 (27.8)

8 (50.0)

Presence of DVT

10 (18.9)

4 (22.2)

6 (37.5)

0.28*

0.19*

Mortality

2 (3.8)

4 (22.2)

4 (25.0)

0.012*

0.081*

Localization of embolism

0.051*

0.015*

Pulmonary artery

14 (26.4)

8 (44.4)

5 (31.3)

Lobar artery

18 (34.0)

5 (27.8)

4 (25.0)

Segmental artery

16 (30.2)

3 (16.7)

2 (12.5)

Subsegmental artery

4 (7.5)

1 (5.6)

-

Extensive

1 (1.9)

1 (5.6)

5 (31.3)

Unilateral

20 (37.7)

5 (27.8)

7 (43.8)

0.61

0.52

Bilateral

33 (62.3)

13 (72.2)

9 (56.3)

Favipiravir treatment

47 (88.7)

17 (94.4)

10 (62.5)

0.021*

0.012*

HCQ treatment

12 (22.6)

5 (27.8)

7 (43.8)

0.27*

0.13*

Methylprednisolone (> 250 mg/d)

4 (7.5)

4 (22.2)

1 (6.3)

0.22*

1.00*

Median PESI score (IQR)

77.0 (36.0)

123.5 (56.0)

108.5 (21.0)

< 0.001

0.021

Median MPA diameter, mm (IQR)

26.6 (5.0)

29.9 (4.8)

30.9 (6.1)

0.013

0.080

Median RV/LV ratio (IQR)

1.03 (0.23)

1.13 (0.20)

1.35 (0.57)

0.005

0.004

Median PAP, mmHg (IQR)

31.5 (11.0)

35.0 (-)

50.0 (16.0)

0.003

< 0.001

Median tricuspid valve regurgitation grade (IQR)

1.0 (0.0)

1.0 (-)

1.75 (1.5)

0.033

0.029

Median d-dimer, mg/L (IQR)

4.0 (6.0)

10.1 (25.0)

11.3 (19.0)

0.051

0.16

Median troponin, ng/L (IQR)

6.0 (22.0)

13.0 (34.3)

20.5 (88.0)

0.037

0.030

Median BNP, ng/L (IQR)

147.5 (617.0)

202.0 (1604.0)

877.0 (11280.0)

0.13

0.081